Equities

Xencor Inc

Xencor Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)24.32
  • Today's Change0.216 / 0.89%
  • Shares traded164.87k
  • 1 Year change+29.82%
  • Beta0.6618
Data delayed at least 15 minutes, as of Nov 22 2024 17:38 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform6
Hold1
Sell1
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for Xencor Inc have a median target of 34.00, with a high estimate of 59.00 and a low estimate of 20.00. The median estimate represents a 41.08% increase from the last price of 24.10.
High144.8%59.00
Med41.1%34.00
Low-17.0%20.00

Earnings history & estimates in USD

On Nov 06, 2024, Xencor Inc reported 3rd quarter 2024 losses of -0.71 per share. This result exceeded the -0.98 consensus loss of the 10 analysts covering the company and under-performed last year's 3rd quarter results by 77.50%.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate-49.58%
Xencor Inc reported annual 2023 losses of -2.08 per share on Feb 27, 2024.
Average growth rate-123.66%
More ▼

Revenue history & estimates in USD

Xencor, Inc. had 3rd quarter 2024 revenues of 10.71m. This missed the 13.29m consensus estimate of the 9 analysts following the company. This was 43.52% below the prior year's 3rd quarter results.
Average growth rate-25.05%
Xencor, Inc. had revenues for the full year 2023 of 168.34m. This was 2.28% above the prior year's results.
Average growth rate+16.16%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.